RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
+$791M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
$15.7M |
| 2 |
Eli Lilly
LLY
|
$12.6M |
| 3 |
Encompass Health
EHC
|
$12.1M |
| 4 |
Cardinal Health
CAH
|
$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 2 |
Oscar Health
OSCR
|
$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
$14.9M |
| 4 |
UnitedHealth
UNH
|
$14.7M |
| 5 |
McKesson
MCK
|
$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $45.1M | 5.7% | 57,870 +16,120 | +39% | +$12.6M |
|
2
Boston Scientific
BSX
$156B
| $31.8M | 4.02% | 296,000 -4,000 | -1% | -$430K |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $27.4M | 3.46% | 61,455 -5,295 | -8% | -$2.36M |
|
4
Glaukos
GKOS
$5.5B
| $24.3M | 3.07% | 235,000 -35,000 | -13% | -$3.62M |
|
5
Intuitive Surgical
ISRG
$170B
| $24.1M | 3.05% | 44,350 -7,150 | -14% | -$3.89M |
|
6
Tenet Healthcare
THC
$16.3B
| $24M | 3.04% | 136,429 +9,729 | +8% | +$1.71M |
|
|
7
Danaher
DHR
$147B
| $24M | 3.03% | 121,452 +79,500 | +190% | +$15.7M |
|
8
CVS Health
CVS
$92.8B
| $20.4M | 2.58% | 295,362 +59,500 | +25% | +$4.1M |
|
|
9
McKesson
MCK
$85.4B
| $20.3M | 2.57% | 27,717 -19,500 | -41% | -$14.3M |
|
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $18.8M | 2.37% | 149,217 +59,400 | +66% | +$7.47M |
|
11
Gilead Sciences
GILD
$140B
| $18.6M | 2.36% | 168,150 -65,350 | -28% | -$7.25M |
|
12
Exact Sciences
EXAS
$8.98B
| $18.6M | 2.35% | 350,000 -90,000 | -20% | -$4.78M |
|
13
Alignment Healthcare
ALHC
$3.24B
| $18M | 2.28% | 1,287,284 -50,000 | -4% | -$700K |
|
14
Insmed
INSM
$28.8B
| $17.7M | 2.23% | 175,435 -10,065 | -5% | -$1.01M |
|
15
Elevance Health
ELV
$71.8B
| $17.4M | 2.2% | 44,650 -4,300 | -9% | -$1.67M |
|
|
16
Encompass Health
EHC
$12.3B
| $16.7M | 2.11% | 136,400 +99,000 | +265% | +$12.1M |
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $16.7M | 2.11% | 51,197 +3,000 | +6% | +$978K |
|
18
Medtronic
MDT
$119B
| $15.6M | 1.98% | 179,500 -75,500 | -30% | -$6.58M |
|
19
Cencora
COR
$56.5B
| $14.8M | 1.87% | 49,375 +17,000 | +53% | +$5.1M |
|
20
Regeneron Pharmaceuticals
REGN
$61.5B
| $14.5M | 1.84% | 27,700 -4,050 | -13% | -$2.13M |
|
21
Insulet
PODD
$23.9B
| $14.5M | 1.83% | 46,000 -15,000 | -25% | -$4.71M |
|
22
DexCom
DXCM
$29.5B
| $13.9M | 1.76% | 159,500 +4,500 | +3% | +$393K |
|
23
AbbVie
ABBV
$372B
| $12.9M | 1.63% | 69,375 -19,275 | -22% | -$3.58M |
|
24
Align Technology
ALGN
$10.3B
| $12.6M | 1.59% | 66,500 +25,000 | +60% | +$4.73M |
|
25
Royalty Pharma
RPRX
$15.6B
| $12.4M | 1.57% | 344,000 -67,000 | -16% | -$2.41M |
|